ALNYLAM PHARMACEUTICALS, INC.
Lobbying client. Federal LDA filings.
Connected on the graph
Inbound (16)
| date | from | type | amount | role | source |
|---|---|---|---|---|---|
| — | John Martin | lobbied_for | — | lda_lobbyist_client | |
| — | Sophie Khanahmadi | lobbied_for | — | lda_lobbyist_client | |
| — | Maximilian Walter | lobbied_for | — | lda_lobbyist_client | |
| — | John Kirkland Twomey | lobbied_for | — | lda_lobbyist_client | |
| — | Corey Malmgren | lobbied_for | — | lda_lobbyist_client | |
| — | Jeffrey Carroll | lobbied_for | — | lda_lobbyist_client | |
| — | Sonia Goh | lobbied_for | — | lda_lobbyist_client | |
| — | Alanna Temme | lobbied_for | — | lda_lobbyist_client | |
| — | Jonathon Jones | lobbied_for | — | lda_lobbyist_client | |
| — | John Michael Gonzalez | lobbied_for | — | lda_lobbyist_client | |
| 2026-01-01 | TIBER CREEK GROUP | lobbies_for | $60,000 | lda_filing | |
| 2026-01-01 | CAPITOL COUNSEL LLC | lobbies_for | $60,000 | lda_filing | |
| 2026-01-01 | LMH STRATEGIC SOLUTIONS | lobbies_for | $50,000 | lda_filing | |
| 2025-01-01 | CAPITOL COUNSEL LLC | lobbies_for | — | lda_filing | |
| 2025-01-01 | CAPITOL COUNSEL LLC | lobbies_for | — | lda_filing | |
| 2025-01-01 | LMH STRATEGIC SOLUTIONS | lobbies_for | — | lda_filing |
Outbound (6)
| date | type | to | amount | role | source |
|---|---|---|---|---|---|
| 2026-01-01 | lobbies_on_bill | HR 1672 — Maintaining Investments in New Innovation Act | — | H.R. 1672 | lobbying_bill_mention |
| 2026-01-01 | lobbies_on_bill | HR 946 — ORPHAN Cures Act | — | H.R. 946 | lobbying_bill_mention |
| 2026-01-01 | lobbies_on_bill | S 1862 — ORPHAN Cures Act | — | S. 1862 | lobbying_bill_mention |
| 2026-01-01 | lobbies_on_bill | HR 1672 — Maintaining Investments in New Innovation Act | — | H.R.1672 | lobbying_bill_mention |
| 2026-01-01 | lobbies_on_bill | HR 946 — ORPHAN Cures Act | — | H.R.946 | lobbying_bill_mention |
| 2026-01-01 | lobbies_on_bill | S 1862 — ORPHAN Cures Act | — | S.1862 | lobbying_bill_mention |
- Source id
64701- General description
- Pharmaceutical manufacturer.
- State
- MA
- Country
- US
- Principal place of business
- US
- Effective date
- 2025-02-01
- Total spend (across 3 ingested filings)
- $60,000
Filings
| Posted | Type | Year | Lobbying firm | Income |
|---|---|---|---|---|
| 2026-04-16 | Q1 | 2026 | CAPITOL COUNSEL LLC | $60,000 |
| 2025-03-07 | RA | 2025 | CAPITOL COUNSEL LLC | — |
| 2025-03-07 | RR | 2025 | CAPITOL COUNSEL LLC | — |